脐带来源间充质干细胞治疗异基因造血干细胞移植后慢性移植物抗宿主病

背景：间充质干细胞具有免疫调节作用,在治疗急性移植物抗宿主病中已取得成功,但是在治疗慢性移植物抗宿主病中,特别是肺部慢性移植物抗宿主病的研究报道还很少。目的：评价脐带间充质干细胞治疗造血干细胞移植后慢性移植物抗宿主病的效果。方法：10例接受异基因干细胞移植治疗患者,明确诊断为慢性移植物抗宿主病,常规免疫抑制治疗无效,给予脐带间充质干细胞治疗,每个治疗剂量2×107个细胞,每次1或2个剂量,每2周治疗1次,根据疗效标准评价疗效。结果与结论：4例肺部慢性移植物抗宿主病患者3例显效,2例皮肤型慢性移植物抗宿主病患者1例进步,1例显效;4例肝脏排斥患者2例显效,2例无效,治疗总有效率70%（7/10）。结果表明脐带间充质干细胞治疗难治性慢性移植物抗宿主病是一个有效的疗法。

Treatment of chronic graft-versus-host disease with human umbilical cord mesenchymal stem cells

BACKGROUND： Mesenchymal stem cells have immunomodulatory effects, which have been proven to be successful in treating acute greft-versus-host disease. However, there are fewer reports concerning human umbilical cord mesenchymal stem cells in treating chronic greft-versus-host disease, particularly for lung-type chronic greft-versus-host disease. OBJECTIVE： To evaluate the effect of human umbilical cord mesenchymal stern cells to treat chronic graft-versus-host disease after hematopoietic stem cell transplantation. METHODS： Ten patients undergoing allo-hematopoietic stern cell treatment were clearly diagnosed as having chronic graft-versus-host disease, and had no improvement after conventional immunosuppressive therapy. These patients received the treatment of human umbilical cord mesenchymal stem cells, 2x 107 cells per curative unit, 1-2 units every two weeks. The therapeutic results were evaluated according to the clinical standards. RESULTS AND CONCLUSION： In four patients with lung-type chronic graft-versus-host disease, three patients were effective. In two patients with skin-type chronic graft-versus-host disease, one patient had progress, and another one was effective. In four patients of liver rejection, two patients were effective and the other two were ineffective. The total effective rate was 70% （7/10）. Human umbilical cord mesenchymal stem cell infusion can be effective to refractory chronic graft-versus-host disease.